Business Context and Reporting Period
Capstone Therapeutics Corp. filed this Form 10-K for the fiscal year ended December 31, 2017. The filing identifies the registrant as Capstone Therapeutics Corp., although the request metadata identifies Capstone Holding Corp.; investors should verify the issuer name.
The company is a development-stage biotechnology business with no revenue-generating operations. Its principal asset is its investment in LipimetiX Development, Inc., a joint venture developing the Apo E mimetic peptide AEM-28 and analogs for severe lipid disorders and related cardiovascular indications. The company operates virtually and uses consultants for administrative, regulatory, and research activities.
AEM-28 Phase 1a and Phase 1b/2a trials in Australia were completed in 2014. The company reported generally acceptable safety results and statistically significant pharmacodynamic effects in multiple lipid biomarkers, but no product candidate has been approved for sale.
Key Financial Metrics
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Revenue | None reported | None reported | No revenue-generating operations |
| General and administrative expense | $641,000 | $543,000 | Up $98,000 |
| Research and development expense | $1.039 million | $1.041 million | Down $2,000 |
| Total operating expenses | $1.680 million | $1.584 million | Up $96,000 |
| Interest and other expense, net | $111,000 | $81,000 | Up $30,000 |
| Net loss | $1.755 million | $1.609 million | Up $146,000 |
| Net loss attributable to Capstone stockholders | $1.755 million | $663,000 | Up $1.092 million |
| Basic and diluted loss per share | $0.04 | $0.02 | Increased |
| Cash flow used in operating activities | $1.561 million | $1.259 million | Outflow increased $302,000 |
| Cash and cash equivalents at year-end | $1.275 million | $698,000 | Up $577,000 |
| Total assets | $1.569 million | $1.182 million | Up $387,000 |
| Total equity | $(879,000) | $(122,000) | Deficit increased |
Gross margin, operating margin, and cash-conversion measures are not meaningful because the company reported no revenue. The filing does not provide a clear quarterly-only Q4 financial breakdown; the reported figures are for the full fiscal year.
At December 31, 2017, current liabilities were $199,000 and long-term debt was $2.249 million, consisting primarily of secured debt and accrued interest. The company had approximately $1.076 million of negative working capital based on reported current assets and current liabilities, excluding the long-term debt.
Material Changes Versus the Prior Comparable Period
- Net loss attributable to Capstone stockholders increased to $1.755 million from $663,000. The 2016 loss benefited from $946,000 of losses allocated to LipimetiX Series B-1 preferred stockholders; no comparable noncontrolling-interest allocation reduced the 2017 attributable loss.
- General and administrative expense increased 18%, primarily because 2017 included audit fees for the 2016 and 2015 financial statements.
- Research and development expense was essentially flat, reflecting continued limited spending through the joint venture.
- Operating cash use increased 24% to $1.561 million.
- In July 2017, the company raised an aggregate $3.440 million from BP Peptides, LLC, comprising approximately $1.013 million from newly issued common stock and a $2.428 million secured loan. Net proceeds were approximately $2.074 million after debt repayment and transaction costs.
- The July financing repaid $1.0 million of convertible promissory notes and $79,000 of accrued interest and resulted in BP Peptides owning approximately 34.1% of the company at year-end.
- In August 2017, the company invested $1.0 million in LipimetiX Series B-2 preferred stock. Its reported as-converted ownership in the joint venture was approximately 62.2% after the financing.
- The company issued 13.5 million common shares in 2017, increasing shares outstanding from approximately 40.9 million to 54.4 million and creating dilution for existing holders.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management expects to maintain a virtual operating model in 2018 and limit development activity unless additional funding is obtained. The company and its joint venture are pursuing fundraising, partnering, licensing, strategic transactions, or other capital sources. Management states that additional funding is required for continued operations and for further AEM-28 development.
- The company reported that the 2017 financing alleviated substantial doubt about its ability to continue as a going concern, but additional funding remains necessary to achieve development objectives and continue planned operations.
- The secured debt bears interest at 6% and was due October 15, 2020. It is secured by substantially all company assets. In January 2018, interest payments were deferred until maturity in exchange for a warrant to purchase up to 6,321,930 common shares at $0.075 per share.
- The joint venture had no active clinical trials at December 31, 2017 and cannot conduct additional material development without funding. Future trials depend on regulatory approvals, financing, and other conditions.
- The company has invested $6.0 million in the joint venture and had advanced approximately $1.640 million, including accrued interest, through December 31, 2017. The company could absorb additional joint venture losses, including $667,000 previously allocated to noncontrolling common interests, if the joint venture fails to continue.
- Key risks include inability to obtain funding, failure to obtain regulatory approval, unfavorable clinical or preclinical results, competition, intellectual-property challenges, dependence on consultants and third parties, product liability, limited liquidity of the OTCQB-traded stock, and potential dilution from future equity issuance.
- The company maintains no product liability insurance, although it was not conducting clinical trials at year-end.
- Management identified a material weakness in internal control over financial reporting during 2017 related to incorrect classification of convertible notes in previously filed quarterly reports. Additional financial-statement review controls were implemented in the fourth quarter to remediate the weakness. The independent auditor did not provide an attestation opinion on internal control effectiveness.
- The filing reports an approximately $38 million valuation allowance against deferred tax assets at December 31, 2017, including substantial federal and state net operating loss carryforwards. The ability to use these tax attributes may be limited by future ownership changes.
Investor Verification Priorities
- Verify the correct issuer identity, as the request metadata says Capstone Holding Corp. while the filing names Capstone Therapeutics Corp.
- Review the audited financial statements and notes for the going-concern assessment, the $2.249 million secured-debt balance, and the terms of the BP Peptides financing.
- Assess cash runway against the $1.561 million 2017 operating cash burn and confirm the portion of cash held by the joint venture.
- Evaluate whether additional financing, licensing, or partnering has been obtained since the filing date and the resulting dilution or control effects.
- Review the January 2018 warrant issuance to BP Peptides and its potential effect on ownership and dilution.
- Confirm the current development status, funding requirements, regulatory pathway, and intellectual-property position for AEM-28 and its analogs.
- Monitor remediation of the internal-control weakness and any SEC or OTCQB response to prior filing and auditor issues.